Physician profile
Faisal Mahfooz
NPI 1699336164
$3,502.49
in general payments reported to CMS, 2019-2025
19 companies · $69.26 in 2025
The $69.26 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $480 · 2023: $2,303 · 2024: $651 · 2025: $69.26.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531 · Travel and Lodging: $492.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,530.54 |
| Travel and Lodging | $492.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $1,522.58 | 2022-2024 | Emerge Push, Crossboss |
| Abbott Laboratories | $770.59 | 2023-2025 | Ensite, Amplatzer Talisman, Thoratec Heartmate 3 Lvas Implant Kit |
| Abiomed | $304.23 | 2023-2024 | Impella |
| Astellas Pharma US INC | $190.98 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.35 | 2023-2025 | Lifevest |
| Novo Nordisk INC | $124.41 | 2024 | |
| Pfizer INC. | $109.74 | 2023 | |
| Novartis Pharmaceuticals Corporation | $92.01 | 2023-2024 | |
| Biosense Webster, INC. | $52.70 | 2022 | |
| Cardiva Medical, INC. | $32.19 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Janssen Pharmaceuticals, INC | $30.49 | 2022 | |
| Aquestive Therapeutics, INC. | $24.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $23.07 | 2024 | Camzyos |
| Impulse Dynamics (USA) INC. | $18.78 | 2022 | |
| Philips North America LLC | $18.16 | 2024 | (Br0) Coronary Atherectomy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.46 | 2023 | Jardiance |
| Edwards Lifesciences Corporation | $14.20 | 2022 | |
| Amgen INC. | $14.14 | 2022 | |
| Merck Sharp & Dohme LLC | $13.88 | 2023 | Verquvo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Faisal Mahfooz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.